By Justin Petrone

CombiMatrix is planning to expand its test menu to hasten its growth in the molecular diagnostics market.

CEO Judd Jessup said during an earnings call last week that the Irvine, Calif.-based firm will introduce specific gene mutation-analysis testing this quarter. To date, the company has outsourced such assays to other labs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.